{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:30Z","timestamp":1788243390940,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02351-9","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T03:21:04Z","timestamp":1782184864000},"page":"1553-1561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relacorilant: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"2351_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040653","author":"R Buonaiuto","year":"2023","unstructured":"Buonaiuto R, Neola G, Cecere SC, et al. Glucocorticoid receptor and ovarian cancer: from biology to therapeutic intervention. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13040653.","journal-title":"Biomolecules"},{"key":"2351_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03009-4","author":"H Karvonen","year":"2020","unstructured":"Karvonen H, Arjama M, Kaleva L, et al. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020. https:\/\/doi.org\/10.1038\/s41419-020-03009-4.","journal-title":"Cell Death Dis"},{"key":"2351_CR3","unstructured":"Corcept Therapeutics. FDA approves Corcept's selective glucocorticoid receptor antagonist LIFYORLI\u2122 (relacorilant) plus nab-paclitaxel for treatment of patients with platinum-resistant ovarian cancer [media release]. 25 Mar 2026. https:\/\/ir.corcept.com\/news-releases\/news-release-details\/fda-approves-corcepts-selective-glucocorticoid-receptor\/."},{"key":"2351_CR4","unstructured":"Corcept Therapeutics Incorporated. LIFYORLI\u2122 (relacorilant) capsules, for oral use: US prescribing information. 2026. https:\/\/corcept.com\/wp-content\/uploads\/Lifyorli_PI.pdf. Accessed 8 May 2026."},{"key":"2351_CR5","unstructured":"Corcept Therapeutics. Corcept to present late-breaking data from pivotal phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer at ASCO 2025 [media release]. 23 Apr 2025. http:\/\/www.corcept.com."},{"key":"2351_CR6","unstructured":"Corcept Therapeutics. Corcept Therapeutics announces second quarter 2019 financial results and provides corporate update [media release]. 1 Aug 2019. http:\/\/www.corcept.com."},{"key":"2351_CR7","unstructured":"Corcept Therapeutics. Corcept Therapeutics announces first quarter 2019 financial results and provides corporate update [media release]. 9 May 2019. http:\/\/www.corcept.com."},{"key":"2351_CR8","unstructured":"Corcept Therapeutics. Corcept Therapeutics receives Orphan Designation for relacorilant as treatment for pancreatic cancer [media release]. 1 Oct 2018. http:\/\/www.corcept.com."},{"key":"2351_CR9","doi-asserted-by":"crossref","unstructured":"Corcept Therapeutics. Corcept Therapeutics announces third quarter 2018 financial results and provides corporate update [media release]. 1 Nov 2018. http:\/\/www.corcept.com.","DOI":"10.1016\/j.fos.2018.01.043"},{"key":"2351_CR10","unstructured":"Corcep Therapeutics. Corcept submits Marketing Authorization Application to European Medicines Agency for relacorilant as a treatment for patients with platinum-resistant ovarian cancer [media release]. 14 Oct 2025. http:\/\/www.corcept.com."},{"key":"2351_CR11","unstructured":"Corcept Therapeutics. FDA files Corcept's New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer [media release]. 10 Sep 2025. http:\/\/www.corcept.com."},{"key":"2351_CR12","doi-asserted-by":"crossref","unstructured":"Hunt H, Belanoff J, Block T, et al. Preclinical efficacy of the selective GR antagonist, CORT125134 [abstract no. 3623]. Cancer Res. 2017;77(13_Suppl).","DOI":"10.1158\/1538-7445.AM2017-3623"},{"issue":"2 Suppl 1","key":"2351_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.103997","volume":"36","author":"SJ Baron","year":"2026","unstructured":"Baron SJ, Kaushik S, Hunt H, et al. Evaluation of relacorilant as a glucocorticoid receptor modulator for maintenance therapy following standard first-line treatment in ovarian cancer organoid models [abstract no. 1721]. Int J Gynecol Cancer. 2026;36(2 Suppl 1):103997.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"2351_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eprac.2023.09.011","volume":"30","author":"DM Donegan","year":"2024","unstructured":"Donegan DM, Pivonello R, Stigliano A, et al. Relacorilant, a selective glucocorticoid receptor modulator in development for the treatment of patients with Cushing syndrome, does not cause prolongation of the cardiac QT interval. Endocr Pract. 2024;30(1):11\u20138.","journal-title":"Endocr Pract"},{"issue":"4","key":"2351_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpdd.389","volume":"7","author":"H Hunt","year":"2018","unstructured":"Hunt H, Donaldson K, Strem M, et al. Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study. Clin Pharmacol Drug Dev. 2018;7(4):408\u201321.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"2","key":"2351_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jcph.1731","volume":"61","author":"JM Custodio","year":"2021","unstructured":"Custodio JM, Donaldson KM, Hunt HJ. An in vitro and in vivo evaluation of the effect of Relacorilant on the activity of cytochrome P450 drug metabolizing enzymes. J Clin Pharmacol. 2021;61(2):244\u201353.","journal-title":"J Clin Pharmacol"},{"issue":"10496","key":"2351_CR17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","volume":"405","author":"AB Olawaiye","year":"2025","unstructured":"Olawaiye AB, Gladieff L, O\u2019Malley DM, et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025;405(10496):2205\u201316.","journal-title":"Lancet"},{"issue":"30","key":"2351_CR18","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.22.02624","volume":"41","author":"N Colombo","year":"2023","unstructured":"Colombo N, Van Gorp T, Matulonis UA, et al. Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study. J Clin Oncol. 2023;41(30):4779\u201389.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2351_CR19","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/oncolo\/oyae210","volume":"29","author":"EH Borazanci","year":"2024","unstructured":"Borazanci EH, Bahary N, Chung V, et al. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Oncologist. 2024;29(11):957\u201365.","journal-title":"Oncologist"},{"issue":"11","key":"2351_CR20","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1158\/1078-0432.CCR-23-3636","volume":"30","author":"KB Desai","year":"2024","unstructured":"Desai KB, Serritella AV, Stadler WM, et al. A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration-resistant prostate cancer [abstract]. Clin Cancer Res. 2024;30(11):2384\u201392.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2351_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-8587(25)00362-6","volume":"14","author":"R Pivonello","year":"2026","unstructured":"Pivonello R, Arnaldi G, Auchus RJ, et al. Efficacy and safety of relacorilant for the treatment of patients with Cushing\u2019s syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. Lancet Diabetes Endocrinol. 2026;14(4):291\u2013304.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9 Suppl","key":"2351_CR22","first-page":"S203","volume":"31","author":"AH Hamrahian","year":"2025","unstructured":"Hamrahian AH, Aresta C, Badiu C, et al. Efficacy and safety of relacorilant in patients with adrenal hypercortisolism: results from a phase 3 study [abstract plus poster]. Endocr Pract. 2025;31(9 Suppl):S203.","journal-title":"Endocr Pract"},{"key":"2351_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662865","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Bancos I, Feelders RA, et al. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. Front Endocrinol (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fendo.2021.662865.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2351_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156213","author":"RJ Auchus","year":"2025","unstructured":"Auchus RJ, Gilis-Januszewska A, Badiu C, et al. Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome) [abstract no. 0048 plus presentation]. Metabolism. 2025. https:\/\/doi.org\/10.1016\/j.metabol.2025.156213.","journal-title":"Metabolism"},{"issue":"9 Suppl","key":"2351_CR25","first-page":"S174","volume":"31","author":"ZC Hannoush","year":"2025","unstructured":"Hannoush ZC, Badiu C, Davila C, et al. A comprehensive safety assessment of relacorilant: Insights from phase 2 and phase 3 trials in patients with endogenous hypercortisolism [abstract plus poster]. Endocr Pract. 2025;31(9 Suppl):S174\u20135.","journal-title":"Endocr Pract"},{"issue":"Suppl 2","key":"2351_CR26","doi-asserted-by":"publisher","first-page":"S748","DOI":"10.1016\/j.annonc.2025.11.012","volume":"36","author":"D Lorusso","year":"2025","unstructured":"Lorusso D, Monk BJ, Park JY, et al. BELLA: a phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer [abstract no. 1239eTiP plus poster]. Ann Oncol. 2025;36(Suppl 2):S748.","journal-title":"Ann Oncol"},{"key":"2351_CR27","unstructured":"Corcept Therapeutics. Corcept Therapeutics announces fourth quarter and full-year 2025 audited financial results, provides corporate update [media release]. 24 Jan 2026. http:\/\/www.corcept.com."},{"key":"2351_CR28","doi-asserted-by":"crossref","unstructured":"Atiq MO, Page A, Catenacci M, et al. High-risk localized prostate cancer treated with neoadjuvant LHRH agonist\/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo [abstract no. TPS415]. J Clin Oncol. 2026;44(7_Suppl).","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS415"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02351-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:44Z","timestamp":1788242564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02351-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2351"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02351-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}